Race Oncology Ltd. (AU:RAC) has released an update.
Race Oncology Ltd is set to present at the 18th Bioshares Biotech Summit, highlighting the significance of reducing cardiovascular toxicity in cancer treatments. Executive Director, Dr. Pete Smith, will discuss the company’s lead compound, bisantrene, focusing on its clinical advantages, including less cardiotoxicity and its reformulation RC220 for enhanced anti-cancer effects. The company is actively seeking partnerships to expand global access to bisantrene for cancer patients.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.
